INTRAVENOUS BRINCIDOFOVIR EFFECTIVELY REDUCES CMV DNAEMIA IN ANTIVIRAL EXPERIENCED IMMUNOCOMPROMISED PATIENTS: RESULTS OF A PHASE 2A CLINICAL TRIAL (EBMT 2026) - Feb 7, 2026 - Abstract #OS09-07; Pres time: Mar 24, 2026; 09:54 AM - 10:03 AM; Location: N104; P2 | "Brincidofovir (BCV) is a lipid conjugate of cidofovir that overcomes cidofovir's dose-limiting nephrotoxicity while enhancing antiviral activity against CMV and other double-stranded DNA viruses...Most patients (7/9 per Cohort) had failed ≥1 prior CMV antiviral (n=12 GCV or valGCV, 4 foscarnet, 4 letermovir, and 2 maribavir)... IV BCV was effective in reducing CMV DNAemia and was reasonably well tolerated in this population of pre-treated immunocompromised patients with CMV viremia. IV BCV is a potential treatment option for these patients with limited treatment options. These data support further study of IV BCV for treatment of CMV infections in immunocompromised patients."
Clinical • P2a data • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease
|
|
Fareed Khawaja1; Genovefa Papanicolaou2; Michael Grimley3; Carlos A. Gomez4; Kris Mahadeo5; Caitlin Elgarten6; Gabriela Maron7; Randall Lanier8; Ingrid Nielsen-Orzeck8; Rochelle Maher8; Nkechi Azie8; Roy F. Chemaly1
|